RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (MARKET WIRE) -- March 27, 2007 -- Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company has initiated a Phase I trial of the combination of systemic ADH-1 plus isolated limb infusion melphalan for the treatment of melanoma. The study, which will be conducted at Duke University Medical Center, is expected to enroll up to 25 patients with N-cadherin positive melanoma and conclude in the second half of 2007.
